Roots Analysis has done a detailed study on Virtual
Clinical Trial Service Providers Market, 2020-2050, covering key
aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 280+ page report, which features 180+ figures
and 230+ tables, please visit this link
Key market Insights
§ Currently, many companies claim to
have advanced technology platforms, which enable them to decentralize the
clinical research process, thereby, optimizing associated costs and the total
time spent on conducting trials
§ The virtual clinical trials
landscape is presently dominated by the presence of small-sized companies;
majority of the players are headquartered in North America
§ Considering the cost and time-related benefits of using
modern technology solutions in clinical research, several investors have opted
to fund the initiatives of companies engaged in the development of such
solutions
§ Case Study: Pharmaceutical players have already conducted a number of virtual
clinical studies, mostly upon encountering constraints with the conventional
approach and developing the means to overcome them
§ The annual number of virtual
trials, across different therapeutic areas, is on the rise; leveraging
telehealth platforms and remote monitoring systems, both small and established
companies are using this format
§ The rising interest of stakeholders in decentralized
clinical trials is evident in the growing partnership activity; companies inked
deals based on a variety of collaboration models and applications, worldwide
§ Owing to the tremendous rise in
cost and complexity of conventional clinical research, the market opportunity
for virtual clinical trials is poised to grow at a CAGR of 14% till 2050
§ The projected opportunity within
the virtual clinical trials market is expected to be well distributed within
different phases of development and end users, across the globe
For more information, please visit https://www.rootsanalysis.com/reports/virtual-clinical-trial-service-provides-market.html
Table of Contents
1. PREFACE
1.1. Scope of the
Report
1.2. Research
Methodology
1.3. Key
Questions Answered
1.4. Chapter
Outlines
2. EXECUTIVE
SUMMARY
3. INTRODUCTION
3.1. Chapter
Overview
3.2. Existing Constraints
in Clinical Research
3.2.1. Increasing Complexity and Cost of Trials
3.2.2. Evolving
Regulatory Standards
3.2.3. Patient
Recruitment and Retention Challenges
3.2.4. Data
Handling-related Concerns
3.3. Virtual
Clinical Trials
3.3.1. Key Aspects
of Virtual Clinical Trials
3.3.1.1. Study Design
3.3.1.2. Patient Recruitment and Retention
3.3.1.3. Remote Monitoring
3.4.1.4. Data Collection and Analysis
3.3.2. Advantages
and Disadvantages of Virtual Clinical Trials
3.4. Emerging Trends
in Clinical Drug Development
3.4.1. Innovative
Trial Designs
3.4.2. Real-world
Evidence
3.4.3. Patient
Centricity
3.4.4. Big Data
Analytics
3.4.5. Blockchain
Technology
3.5. Future
Perspectives
4. VIRTUAL
CLINICAL TRIAL SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
.1. Chapter
Overview
4.2. Virtual
Clinical Trial Service Providers: Overall Market Overview
4.2.1. Analysis by
Year of Establishment
4.2.2. Analysis by
Company Size
4.2.3. Analysis by
Geography
4.2.4. Analysis by Type of Service Offered
5. COMPANY
PROFILES
5.1. Chapter
Overview
5.2. Cambridge
Cognition
5.2.1. Company
Overview
5.2.2. Technology
Overview
5.2.3. Recent
Developments and Future Outlook
5.3. Center Point
Clinical Services
5.3.1. Company
Overview
5.3.2. Technology
Overview
.3.3. Recent
Developments and Future Outlook
5.4. eClinicalHealth
5.4.1. Company
Overview
5.4.2. Technology
Overview
5.4.3. Recent
Developments and Future Outlook
5.5. IQVIA
5.5.1. Company
Overview
5.5.2. Technology
Overview
5.5.3. Recent
Developments and Future Outlook
5.6. Mytrus
(Medidata Solutions)
5.6.1. Company
Overview
5.6.2. Technology
Overview
5.6.3. Recent
Developments and Future Outlook
5.7. PanAmerican
Clinical Research
5.7.1. Company
Overview
5.7.2. Technology
Overview
5.7.3. Recent
Developments and Future Outlook
5.8. Science 37
5.8.1. Company
Overview
5.8.2. Technology
Overview
5.8.3. Recent Developments
and Future Outlook
5.9. VirTrial
5.9.1. Company
Overview
5.9.2. Technology
Overview
5.9.3. Recent
Developments and Future Outlook
6. CASE STUDY:
VIRTUAL CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA PLAYERS
6.1. Chapter
Overview
6.2. Virtual
Clinical Trial-Related Initiatives of Big Pharma Players
6.2.1. Pfizer
6.2.1.1. Initial
Approach and Key Learnings
6.2.1.2. Future
Perspective
6.2.2. Johnson &
Johnson
6.2.2.1. Initial
Approach and Key Learnings
6.2.2.2. Future
Perspective
6.2.3. Sanofi
6.2.3.1. Initial
Approach and Key Learnings
6.2.3.2. Future
Perspective
6.2.4. Novartis
6.2.4.1. Initial
Approach and Key Learnings
6.2.4.2. Future
Perspective
6.2.5. GlaxoSmithKline
6.2.5.1. Initial
Approach and Key Learnings
6.2.5.2. Future
Perspective
6.2.6. Amgen
6.2.6.1. Initial
Approach and Key Learnings
6.2.6.2. Future
Perspective
6.2.7. AstraZeneca
6.2.7.1. Initial
Approach and Key Learnings
6.2.7.2. Future Perspective
7. CASE STUDY:
TRADITIONAL VERSUS VIRTUAL CRO
7.1. Chapter
Overview
7.2. Comparison
between Traditional and Virtual CROs
7.3. Key
Attributes of a Virtual CRO
7.4. The Virtual
Operating Model
7.5. Concluding
Remarks
8. FUNDING AND
INVESTMENT ANALYSIS
8.1. Chapter
Overview
8.2. Types of
Funding
8.3. Virtual
Clinical Trial Service Providers: Funding and Investment Analysis
8.3.1. Analysis by
Year of Investment
8.3.2. Analysis by
Amount Invested
8.3.3. Analysis by Type
of Funding
8.3.4. Most Active
Players
8.3.5. Most Active
Investors
8.4. Concluding
Remarks
9. PARTNERSHIPS
& COLLABORATIONS
9.1. Chapter
Overview
9.2. Partnership
Models
9.3. Virtual
Clinical Trial Service Providers: Partnership and Collaborations
9.3.1. Analysis by
Year of Partnership
9.3.2. Analysis by
Type of Partnership
9.3.3. Analysis by
Focus Area Mentioned in Agreement
9.3.4. Analysis by
Target Therapeutic Area Mentioned in Agreement
9.3.5. Analysis by
Year of Partnership and Type of Partner
9.3.6. Most Active
Players: Analysis by Number of Partnerships
9.3.7. Geographical
Analysis
9.3.9. Intercontinental
and Intracontinental Agreements
10. COVID-19
IMPACT
10.1. Chapter
Overview
10.2. Impact of
COVID-19 on Clinical Trials
10.3. Impact on
Future Opportunity for Virtual Clinical Trials Service Providers
11. CLINICAL
TRIAL ANALYSIS
11.1. Chapter
Overview
11.2. Scope and
Methodology
11.3. Virtual
Clinical Trials: Clinical Trial Analysis
11.3.1. Analysis by
Trial Registration Year
11.3.2. Analysis by
Trial Phase
11.3.3. Analysis by
Trial Status
11.3.4. Analysis by
Trial Design
11.3.5. Analysis by
Type of Sponsor
11.3.6. Analysis by
Target Therapeutic Area
11.3.7. Geographical Analysis by Number of Registered Trials
11.3.8. Geographical Analysis by Number of Patients Enrolled
12. MARKET
OPPORTUNITY ASSESSMENT
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Virtual Clinical Trial Service Providers: Overall
Market Opportunity, 2020-2050
12.3.1. Virtual Clinical Trial Service Providers Market
Opportunity, 2020-2050: Distribution by Therapeutic Area
12.3.2. Virtual Clinical Trials Service Providers Market
Opportunity, 2020-2050: Distribution by End-user
12.3.3. Virtual Clinical Trials Service Providers Market
Opportunity, 2020-2050: Distribution by Trial Phase
12.3.4. Virtual Clinical Trials Service Providers Market
Opportunity, 2020-2050: Distribution by Geography
12.4. Virtual Clinical Trial Services Market in North
America, 2020-2050
12.4.1. Virtual Clinical Trial Services Market in North America:
Distribution by Therapeutic Area, 2020-2050
12.4.1.1. Virtual Clinical Trial Services Market for Cardiovascular
Disorders in North America, 2020-2050
12.4.1.1.1. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.1.1.2. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.1.1.3. Virtual Clinical
Trial Services Market for Cardiovascular Disorders in North America, 2020-2050:
Share of Phase III Studies
12.4.1.1.4. Virtual Clinical
Trial Services Market for Cardiovascular Disorders in North America, 2020-2050:
Share of Phase IV Studies
12.4.2.1. Virtual
Clinical Trial Services Market for Infectious Disorders in North America,
2020-2050
12.4.2.1.1. Virtual Clinical Trial Services Market for
Infectious Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.2.1.2. Virtual Clinical
Trial Services Market for Infectious Disorders in North America, 2020-2050:
Share of Phase II Studies
12.4.2.1.3. Virtual Clinical
Trial Services Market for Infectious Disorders in North America, 2020-2050:
Share of Phase III Studies
12.4.2.1.4. Virtual Clinical
Trial Services Market for Infectious Disorders in North America, 2020-2050:
Share of Phase IV Studies
12.4.3.1. Virtual
Clinical Trial Services Market for Metabolic Disorders in North America,
2020-2050
12.4.3.1.1. Virtual Clinical
Trial Services Market for Metabolic Disorders in North America, 2020-2050:
Share of Phase I Studies
12.4.3.1.2. Virtual Clinical Trial Services Market for
Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.3.1.3. Virtual Clinical
Trial Services Market for Metabolic Disorders in North America, 2020-2050:
Share of Phase III Studies
12.4.3.1.4. Virtual Clinical
Trial Services Market for Metabolic Disorders in North America, 2020-2050:
Share of Phase IV Studies
12.4.4.1. Virtual Clinical Trial Services Market
for Neurological Disorders in North America, 2020-2050
12.4.4.1.1. Virtual Clinical Trial Services Market for
Neurological Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.4.1.2. Virtual Clinical Trial Services Market for
Neurological Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.4.1.3. Virtual Clinical Trial Services Market for
Neurological Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.4.1.4. Virtual Clinical Trial Services Market for
Neurological Disorders in North America, 2020-2050: Share of Phase IV
Studies
12.4.5.1. Virtual Clinical Trial Services Market for Oncological
Disorders in North America, 2020-2050
12.4.5.1.1. Virtual Clinical Trial Services Market for
Oncological Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.5.1.2. Virtual Clinical Trial Services Market for
Oncological Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.5.1.3. Virtual Clinical Trial Services Market for
Oncological Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.5.1.4. Virtual Clinical Trial Services Market for
Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.6.1. Virtual Clinical Trial Services Market for Respiratory
Disorders in North America, 2020-2050
12.4.6.1.1. Virtual Clinical Trial Services Market
Opportunity for Respiratory Disorders in North America, 2020-2050: Share of
Phase I Studies
12.4.6.1.2. Virtual Clinical Trial Services Market
Opportunity for Respiratory Disorders in North America, 2020-2050: Share of
Phase II Studies
12.4.6.1.3. Virtual Clinical Trial Services Market
Opportunity for Respiratory Disorders in North America, 2020-2050: Share of
Phase III Studies
12.4.6.1.4. Virtual Clinical Trial Services Market
Opportunity for Respiratory Disorders in North America, 2020-2050: Share of
Phase IV Studies
12.4.7.1. Virtual Clinical Trial Services Market for Other Therapeutic
Areas in North America, 2020-2050
12.4.7.1.1. Virtual Clinical Trial Services Market
Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of
Phase I Studies
12.4.7.1.2. Virtual Clinical Trial Services Market
Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of
Phase II Studies
12.4.7.1.3. Virtual Clinical Trial Services Market
Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of
Phase III Studies
12.4.7.1.4. Virtual Clinical Trial Services Market
Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of
Phase IV Studies
12.5. Virtual Clinical Trial Services Market in Europe,
2020-2050
12.5.1. Virtual Clinical Trial Services Market in Europe:
Distribution by Therapeutic Area, 2020-2050
12.5.1.1. Virtual Clinical Trial Services Market for Cardiovascular
Disorders in Europe, 2020-2050
12.5.1.1.1. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.1.1.2. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.1.1.3. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.1.1.4. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.2.1. Virtual Clinical Trial Services Market for Infectious
Disorders in Europe, 2020-2050
12.5.2.1.1. Virtual Clinical Trial Services Market for
Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.2.1.2. Virtual Clinical Trial Services Market for
Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.2.1.3. Virtual Clinical Trial Services Market for
Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.2.1.4. Virtual Clinical Trial Services Market for
Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.3.1. Virtual Clinical Trial Services Market for Metabolic
Disorders in Europe, 2020-2050
12.5.3.1.1. Virtual Clinical Trial Services Market for
Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.3.1.2. Virtual Clinical Trial Services Market for
Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.3.1.3. Virtual Clinical Trial Services Market for
Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.3.1.4. Virtual Clinical Trial Services Market for
Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.4.1. Virtual Clinical Trial Services Market for Neurological
Disorders in Europe, 2020-2050
12.5.4.1.1. Virtual Clinical Trial Services Market for
Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.4.1.2. Virtual Clinical Trial Services Market for
Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.4.1.3. Virtual Clinical Trial Services Market for
Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.4.1.4. Virtual Clinical Trial Services Market for
Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.5.1. Virtual Clinical Trial Services Market for Oncological
Disorders in Europe, 2020-2050
12.5.5.1.1. Virtual Clinical Trial Services Market for
Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.5.1.2. Virtual Clinical Trial Services Market for
Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.5.1.3. Virtual Clinical Trial Services Market for
Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.5.1.4. Virtual Clinical Trial Services Market for
Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.6.1. Virtual Clinical Trial Services Market for Respiratory
Disorders in Europe, 2020-2050
12.5.6.1.1. Virtual Clinical Trial Services Market for
Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.6.1.2. Virtual Clinical Trial Services Market for
Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.6.1.3. Virtual Clinical Trial Services Market for
Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.6.1.4. Virtual Clinical Trial Services Market for
Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.7.1. Virtual Clinical Trial Services Market for Other Therapeutic
Areas in Europe, 2020-2050
12.5.7.1.1. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies
12.5.7.1.2. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies
12.5.7.1.3. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies
12.5.7.1.4. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies
12.6. Virtual Clinical Trial Services Market in
Asia-Pacific, 2020-2050
12.6.1. Virtual Clinical Trial Services Market in Asia-Pacific:
Distribution by Therapeutic Area, 2020-2050
12.6.1.1. Virtual Clinical Trial Services Market for Cardiovascular
Disorders in Asia-Pacific, 2020-2050
12.6.1.1.1. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.1.1.2. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.1.1.3. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.1.1.4. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.2.1. Virtual Clinical Trial Services Market for Infectious
Disorders in Asia-Pacific, 2020-2050
12.6.2.1.1. Virtual Clinical Trial Services Market for
Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.2.1.2. Virtual Clinical Trial Services Market for
Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.2.1.3. Virtual Clinical Trial Services Market for
Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.2.1.4. Virtual Clinical Trial Services Market for
Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.3.1. Virtual Clinical Trial Services Market for Metabolic
Disorders in Asia-Pacific, 2020-2050
12.6.3.1.1. Virtual
Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific,
2020-2050: Share of Phase I Studies
12.6.3.1.2. Virtual Clinical Trial Services Market for
Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.3.1.3. Virtual Clinical Trial Services Market for
Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.3.1.4. Virtual Clinical Trial Services Market for
Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.4.1. Virtual Clinical Trial Services Market for Neurological
Disorders in Asia-Pacific, 2020-2050
12.6.4.1.1. Virtual Clinical Trial Services Market for
Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.4.1.2. Virtual Clinical Trial Services Market for
Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.4.1.3. Virtual Clinical
Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050:
Share of Phase III Studies
12.6.4.1.4. Virtual Clinical Trial Services Market for
Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.5.1. Virtual Clinical Trial Services Market for Oncological
Disorders in Asia-Pacific, 2020-2050
12.6.5.1.1. Virtual Clinical Trial Services Market for
Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.5.1.2. Virtual Clinical Trial Services Market for
Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.5.1.3. Virtual Clinical Trial Services Market for
Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.5.1.4. Virtual Clinical Trial Services Market for
Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.6.1. Virtual Clinical Trial Services Market for Respiratory
Disorders in Asia-Pacific, 2020-2050
12.6.6.1.1. Virtual Clinical Trial Services Market for
Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.6.1.2. Virtual Clinical Trial Services Market for
Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.6.1.3. Virtual Clinical Trial Services Market for
Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.6.1.4. Virtual Clinical Trial Services Market for
Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.7.1. Virtual Clinical Trial Services Market for Other Therapeutic
Areas in Asia-Pacific, 2020-2050
12.6.7.1.1. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.7.1.2. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.7.1.3. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.7.1.4. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.7. Virtual Clinical Trial Services Market in Rest of the
World, 2020-2050
12.7.1. Virtual Clinical Trial Services Market in Rest of the
World: Distribution by Therapeutic Area, 2020-2050
12.7.1.1. Virtual Clinical Trial Services Market for Cardiovascular
Disorders in Rest of the World, 2020-2050
12.7.1.1.1. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I
Studies
12.7.1.1.2. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II
Studies
12.7.1.1.3. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III
Studies
12.7.1.1.4. Virtual Clinical Trial Services Market for
Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV
Studies
12.7.2.1. Virtual Clinical Trial Services Market for Infectious
Disorders in Rest of the World, 2020-2050
12.7.2.1.1. Virtual Clinical Trial Services Market for
Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.2.1.2. Virtual Clinical Trial Services Market for
Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.2.1.3. Virtual Clinical Trial Services Market for
Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III
Studies
12.7.2.1.4. Virtual Clinical Trial Services Market for
Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
12.7.3.1. Virtual Clinical Trial Services Market for Metabolic
Disorders in Rest of the World, 2020-2050
12.7.3.1.1. Virtual Clinical Trial Services Market for
Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.3.1.2. Virtual Clinical Trial Services Market for
Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.3.1.3. Virtual Clinical Trial Services Market for
Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.3.1.4. Virtual Clinical
Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050:
Share of Phase IV Studies
12.7.4.1. Virtual Clinical Trial Services Market for Neurological
Disorders in Rest of the World, 2020-2050
12.7.4.1.1. Virtual Clinical Trial Services Market for
Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I
Studies
12.7.4.1.2. Virtual Clinical Trial Services Market for
Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II
Studies
12.7.4.1.3. Virtual Clinical Trial Services Market for
Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III
Studies
12.7.4.1.4. Virtual Clinical Trial Services Market for
Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV
Studies
12.7.5.1. Virtual Clinical Trial Services Market for Oncological
Disorders in Rest of the World, 2020-2050
12.7.5.1.1. Virtual Clinical Trial Services Market for
Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.5.1.2. Virtual Clinical Trial Services Market for
Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II
Studies
12.7.5.1.3. Virtual Clinical Trial Services Market for
Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III
Studies
12.7.5.1.4. Virtual Clinical Trial Services Market for
Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV
Studies
12.7.6.1. Virtual Clinical Trial Services Market for Respiratory
Disorders in Rest of the World, 2020-2050
12.7.6.1.1. Virtual Clinical Trial Services Market for
Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.6.1.2. Virtual Clinical Trial Services Market for
Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II
Studies
12.7.6.1.3. Virtual Clinical Trial Services Market for
Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III
Studies
12.7.6.1.4. Virtual Clinical Trial Services Market for
Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV
Studies
12.7.7.1. Virtual Clinical Trial Services Market for Other Therapeutic
Areas in Rest of the World, 2020-2050
12.7.7.1.1. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I
Studies
12.7.7.1.2. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II
Studies
12.7.7.1.3. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III
Studies
12.7.7.1.4. Virtual Clinical Trial Services Market for
Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV
Studies
13. CONCLUSION
14. INTERVIEW
TRANSCRIPTS
14.1. Chapter
Overview
14.2. ConsilX
14.2.1. Interview
Transcript: Himanshu Verma, Founder and Chief Executive Officer, ConsilX &
Rajesh Jain, Co-Founder, ConsilX
14.3. EmpiraMed
14.3.1. Interview
Transcript: Greg Erman, President and Chief Executive Officer, EmpiraMed
14.4. Andaman7
14.4.1. Interview Transcript: Phillipe Lemmens, Chief Operating
Officer, Andaman7
14.5. uMotif
14.5.1. Interview Transcript: Jonathan Moshinsky, Head of Market
Strategy, uMotif
15. APPENDIX 1:
TABULATED DATA
16. APPENDIX 2:
LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415